"Performance" Shanghai Pharma's annual net profit is RMB 5.725 billion, an increase of 25.7%, with a dividend of RMB 3.5 per 10 shares
Shanghai Pharma (02607.HK) announced its performance for the fiscal year 2025, with revenue of RMB 283.58 billion, an increase of 3% year-on-year. It recorded a net profit of RMB 5.725 billion, a growth of 25.7%, with earnings per share of RMB 1.54. The final dividend is RMB 3.5 per 10 shares.
Excluding one-time gains and losses, the net profit for the year was RMB 4.721 billion, a decline of 5.6%
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments